Alnylam Pharmaceuticals (ALNY) Common Equity (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Common Equity came in at $1.4 billion in Q2 2026, up 143.83% YoY from $555.3 million in Q2 2025, and up 25.92% on a QoQ basis from $1.1 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Common Equity (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Common Equity data on file, last reported at $1.4 billion in Q2 2026.
- Quarterly Common Equity rose 143.83% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 143.83% YoY) and the FY2025 annual result came in at $789.2 million, up 1076.33% from the prior year.
- Common Equity rose to $1.4 billion in Q2 2026, from $1.1 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.4 billion in Q2 2026 to a low of -$408.1 million in Q2 2023.
- A 5-year average of $200.5 million and a median of $49.7 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity plunged 331.84% — and 2025, when it soared 18207.11%.
- Tracing ALNY's Common Equity over 5 years: stood at -$158.2 million in 2022, then slumped by 39.45% to -$220.6 million in 2023, then surged by 130.41% to $67.1 million in 2024, then jumped by 1076.33% to $789.2 million in 2025, then surged by 71.59% to $1.4 billion in 2026.
- The last three Common Equity figures came in at $1.4 billion (Q2 2026), $1.1 billion (Q1 2026), and $789.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.35 Bn |
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 789.18 Mn |
| Sep 30, 2025 | 233.89 Mn |
| Jun 30, 2025 | 250.59 Mn |
| Mar 31, 2025 | 426.14 Mn |
| Dec 31, 2024 | 67.09 Mn |
| Sep 30, 2024 | 32.35 Mn |
| Jun 30, 2024 | -3.07 Mn |
| Mar 31, 2024 | -219.27 Mn |
| Dec 31, 2023 | -220.64 Mn |
| Sep 30, 2023 | -165.87 Mn |
| Jun 30, 2023 | -408.13 Mn |
| Mar 31, 2023 | -259.24 Mn |
| Dec 31, 2022 | -158.22 Mn |
| Sep 30, 2022 | -67.64 Mn |
| Jun 30, 2022 | 176.04 Mn |
| Mar 31, 2022 | 401.17 Mn |
| Dec 31, 2021 | 588.20 Mn |
| Sep 30, 2021 | 755.89 Mn |